Clinical trials: Cerebral Disorder
Alzheimer's Disease
Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.
This study will evaluate compliance, tolerability, safety, efficacy and caregiver burden of rivastigmine patch 10 cm² treatment in people with Alzheimer's disease (MMSE 10-26) initiating therapy for the first time with a…
- Trial name
- CARE (NCT00731224)
- Testing
- Rivastigmine transdermal patch
- Where
- 40 sites in Australia, Malaysia and 3 more
- Volunteers
- 380 people
- Sponsor
- Novartis Pharmaceuticals
Hyperlipidemias, Atherosclerosis
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
A cholesterol/lipid profile screening project of high risk patients with hyperlipidaemia (secondary prevention) who already receive cholesterol-lowering therapy.
- Conditions
- Hyperlipidemias, Atherosclerosis, Coronary Heart Disease, Carotid Stenosis
- Trial name
- NCT00536796
- Where
- Austria
- Volunteers
- 1,096 people
- Sponsor
- AstraZeneca
Alzheimer Disease
A Multiple Ascending Dose Study of COR388
The study is a randomized, double-blind, placebo-controlled, multiple ascending dose study to assess the safety and tolerability of ascending repeat doses of COR388 HCl in older healthy male and female subjects and a cohort of…
- Trial name
- NCT03418688
- Testing
- COR388
- Where
- 3 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Cortexyme Inc.
Dementia, Alzheimer's Type, Alzheimer's Disease
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants.
- Trial name
- TREMHANCE (NCT07688213)
- Testing
- SAR448851
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Dementia
Fasudil fOr redUcing elopemeNt and Spatial Disorientation
Fasudil, a Rho kinase inhibitor, is believed to reduce wandering behaviors of elopement and getting lost by improving spatial memory and navigation through improvements in hippocampal blood flow. Fasudil is non-sedating.
- Trial name
- FOUND (NCT04793659)
- Testing
- Oral Fasudil 90 mg/day, Oral Fasudil 180 mg/day
- Where
- 11 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Woolsey Pharmaceuticals
Parkinson Disease
Performance of the Paragit Sleeve to Measure and Monitor Motor Symptoms in Patients With Parkinson's Disease
This investigation is undertaken to: Evaluate the accuracy and reliability of the device in measuring and recording motor symptoms associated with Parkinson's Disease (PD), and To assess the safety and tolerability of the device…
- Trial name
- PARPIV23 (NCT06490861)
- Testing
- Paragit
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Paragit ApS
Parkinson Disease
A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
This study is a Phase III, multicentre, randomized, initial double-blind study with subsequent open label phases. The study will havea screening phase (4 weeks), a dose increase effect verification phase (12 weeks), a down…
- Trial name
- NCT01929317
- Testing
- Ropinirole CR 2mg tablet, Ropinirole CR 8mg tablet
- Where
- 17 sites in Japan
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Phenylketonuria
A Study of PTC923 in Participants With Phenylketonuria
The main purpose of this trial is to evaluate the efficacy of PTC923 in reducing blood phenylalanine (Phe) levels in participants with phenylketonuria as measured by mean change in blood Phe levels from baseline to Weeks 5 and 6…
- Trial name
- NCT05099640
- Testing
- PTC923
- Where
- 43 sites in United States, Australia and 13 more
- Volunteers
- 157 people
- Sponsor
- PTC Therapeutics
Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID
The purpose of this multi-center, randomized, double-blind, parallel-group, 26 week study is to compare the efficacy and safety of two different dose levels of Amantadine Extended Release Tablets to placebo for the treatment of…
- Trial name
- ALLAY-LID-II (NCT02153632)
- Testing
- amantadine HCl ER
- Where
- 56 sites in United States, Canada and 3 more
- Volunteers
- 135 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Ischemic Stroke
Amnis Therapeutics Thrombectomy Device-First in Man (FIM) Safety and Performance Study
Prospective, single-arm, open label, Safety and Performance clinical investigation.
- Trial name
- NCT02994563
- Testing
- Thrombectomy Device
- Where
- 4 sites in Spain, Sweden
- Volunteers
- 5 people
- Sponsor
- Amnis Therapeutics
Nervous System Disorders
Dysport® Adult Upper Limb Spasticity
The purpose of this research study is to assess the efficacy of Dysport compared to placebo in improving muscle tone in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury.
- Trial name
- NCT01313299
- Testing
- Botulinum toxin type A
- Where
- 40 sites in United States, Belgium and 7 more
- Volunteers
- 243 people
- Sponsor
- Ipsen
Epilepsies, Partial
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
The study will evaluate the long-term safety and tolerability of pregabalin in pediatric patients, age 1 month through 16 years, with partial onset seizures.
- Trial name
- NCT00448916
- Testing
- Pregabalin
- Where
- 18 sites in United States, Mexico and 1 more
- Volunteers
- 54 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Parkinson's Disease (PD)
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.
- Trial name
- NCT02169440
- Testing
- BIA 9-1067, Warfarin
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Alzheimer's Disease
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the long-term safety and tolerability of Bapineuzumab (AAB-001, ELN115727) in subjects with Alzheimer's disease who participated in study ELN115727-301 or study ELN115727-302.
- Trial name
- NCT00937352
- Testing
- Bapineuzumab
- Where
- 191 sites in United States, Austria and 1 more
- Volunteers
- 896 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Stroke, Chronic Stroke Patients
kTMP-Enhanced Motor Rehabilitation for Chronic Stroke Recovery (KULMINATE) Pilot
kTMP, kilohertz transcutaneous magnetic perturbations, is a low intensity transcranial magnetic stimulation technique that will be used in this study to promote arm/hand rehabilitation in patients who have been disabled by stroke.
- Conditions
- Stroke, Chronic Stroke Patients, Arm Weakness as a Consequence of Stroke
- Trial name
- NCT07631078
- Testing
- kTMP
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Magnetic Tides
Alzheimer Disease
Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill
This is an estimation-focused Phase 2 study designed to explore and quantify treatment-related changes across multiple clinical outcomes in patients with Alzheimer's disease over a 210-day period.
- Trial name
- NCT06597058
- Testing
- MAR
- Where
- 16 sites in United States
- Volunteers
- 121 people
- Sponsor
- Noah Pharmaceuticals, Inc.
Acute Cerebral Ischemia
Field Randomization of Nerinetide (NA-1) Therapy in Early Responders
The purpose of this study is to determine whether nerinetide (NA-1) is effective in reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.
- Trial name
- FRONTIER (NCT02315443)
- Testing
- Nerinetide (NA-1)
- Where
- 4 sites in Canada
- Volunteers
- 532 people
- Sponsor
- NoNO Inc.
Ischemic Stroke
Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke
That the Jan Medical Nautilus NeuroWaveTM system provides significantly higher sensitivity to hyper acute ischemic stroke than does CT.
- Trial name
- NCT01643525
- Testing
- Nautilus NeuroWaveTM System
- Where
- 3 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Jan Medical, Inc.
Parkinson's Disease
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
- Trial name
- NCT00199368
- Testing
- Istradefylline ( KW-6002)
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- Kyowa Kirin, Inc.
Stroke
"Evaluation Of ALBA® Device for Upper Extremity Motor Function In Adults With Subacute And Chronic Acquired Brain Injury"
As part of the rehabilitation techniques, robotic equipment has been introduced for the rehabilitation of the upper extremity with promising results.
- Trial name
- NCT05824416
- Testing
- Experimental: ALBA, Conventional Therapy
- Where
- Chile
- Volunteers
- 32 people
- Sponsor
- uMov
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.